SCHEMBL3175492

SCHEMBL3175492

Oc1ccccc1C1=NOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.44
HTT P42858 1/20 0.44
CASP1 P29466 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HSD17B10 Q99714 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 3/20 0.39
BCL2L1 Q07817 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
IDO1 P14902 2/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8626370 0.77 CRBN (0.41) HPGDNPSR1KMT2AHSD17B10ALOX15
SCHEMBL700746 0.77 ALDH1A1 (0.44) HPGDCASP1NPSR1MEN1KMT2A
SCHEMBL7479018 0.73 CA12 (0.31) ALDH1A1L3MBTL1CA1CA2
SCHEMBL7840064 0.72 CYP2D6 (0.38) HPGDHTTCASP1NPSR1MEN1
SCHEMBL570014 0.71 CHRNB4 (0.42) KMT2AMAPK1ALDH1A1NPC1RAB9A
SCHEMBL14854458 0.70 MKNK1 (0.41)
Oxirane SCHEMBL2207023 0.69 ALDH1A1 (0.52) HPGDHTTHSD17B10ALOX15ALDH1A1
SCHEMBL10583572 0.69 HPGD (0.44) HPGDHTTCASP1NPSR1MEN1
SCHEMBL10343777 0.68
SCHEMBL28574 0.65 ALDH1A1 (0.67) HPGDMEN1KMT2AHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411930-B1 ISOXAZOLINE COMPOUNDS HAVING MIF ANTAGONIST ACTIVITY CYTOKINE PHARMASCIENCES INC (US) 2013-01-16 EP disclosed
US-7662843-B2 Isoxazoline compounds having MIF antagonist activity CYTOKINE PHARMASCIENCES, INC. (US) 2010-02-16 US disclosed
EP-1411930-A4 ISOXAZOLINE COMPOUNDS HAVING MIF ANTAGONIST ACTIVITY CYTOKINE PHARMASCIENCES INC (US) 2007-04-04 EP disclosed
US-20040204464-A1 Isoxazoline compounds having MIF antagonist activity CPSI STOCKHOLDER TRUST 2004-10-14 US disclosed
EP-1411930-A2 ISOXAZOLINE COMPOUNDS HAVING MIF ANTAGONIST ACTIVITY Cytokine Pharmasciences, Inc. (US) 2004-04-28 EP disclosed
WO-2002100332-A2 ISOXAZOLINE COMPOUNDS HAVING MIF ANTAGONIST ACTIVITY CYTOKINE PHARMASCIENCES, INC. (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204464-A1 Isoxazoline compounds having MIF antagonist activity MIF, PGF, HLA-DRB1 HPGD 2136/4885HTT 4757/4885CASP1 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.